Alkermes: Catalyst-Rich Months Ahead for the Pipeline

- Alkermes has three key catalysts ahead for the company that will significantly alter the perceived value of the company

- For ALKS5461, most investors do not see an approval on first pass, which might present an attractive risk/reward profile ahead of the announcement

- For ALKS4230, phase 1 dose escalation data should provide visibility into the potential of the drug (with many investors viewing it as high)

- For ALKS3831, there is a more balanced debate about what weight gain data might be shown in its phase 3 readout in 4Q18

Read More